Tolerability of amodiaquine and sulphadoxine‐pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults

Objective  To assess the tolerability and efficacy of amodiaquine (AQ) + sulphadoxine‐pyrimethamine (SP), the first‐line malaria treatment in Rwanda.

[1]  P. Rosenthal,et al.  Artemisinin versus Nonartemisinin Combination Therapy for Uncomplicated Malaria: Randomized Clinical Trials from Four Sites in Uganda , 2005, PLoS medicine.

[2]  A. Oduro,et al.  A randomized comparative study of chloroquine, amodiaquine and sulphadoxine–pyrimethamine for the treatment of uncomplicated malaria in Ghana , 2005, Tropical medicine & international health : TM & IH.

[3]  C. Karema,et al.  Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria , 2004, Tropical medicine & international health : TM & IH.

[4]  C. Karema,et al.  Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. , 2003, The American journal of tropical medicine and hygiene.

[5]  P. Olliaro,et al.  Amodiaquine for treating malaria. , 2003, The Cochrane database of systematic reviews.

[6]  P. Rosenthal,et al.  Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial , 2001, The Lancet.

[7]  P. Garner,et al.  Systematic review of amodiaquine treatment in uncomplicated malaria , 1996, The Lancet.

[8]  N. Kitteringham,et al.  The mechanism of bioactivation and antigen formation of amodiaquine in the rat. , 1992, Biochemical pharmacology.

[9]  P. Phillips-Howard,et al.  Serious Adverse Drug Reactions to Pyrimethamine-Sulphadoxine, Pyrimethamine-Dapsone and to Amodiaquine in Britain , 1990, Journal of the Royal Society of Medicine.

[10]  N. Kitteringham,et al.  Drug-protein conjugates--XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. , 1988, Biochemical pharmacology.

[11]  N. Ratliff,et al.  Chloroquine neuromyotoxicity. Clinical and pathologic perspective. , 1987, The American journal of medicine.

[12]  K. Neftel,et al.  Amodiaquine induced agranulocytosis and liver damage. , 1986, British medical journal.

[13]  G. Edwards,et al.  FREQUENCY OF SEVERE NEUTROPENIA ASSOCIATED WITH AMODIAQUINE PROPHYLAXIS AGAINST MALARIA , 1986, The Lancet.

[14]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[15]  P. Ringwald,et al.  Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. , 2002, Bulletin of the World Health Organization.

[16]  N. Kitteringham,et al.  Immunogenicity of amodiaquine in the rat. , 1990, International archives of allergy and applied immunology.